Implantable polymeric device for sustained release of dopamine agonist
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/00
A61K-031/48
A61K-009/16
A61L-031/16
A61K-031/485
A61K-031/381
A61K-031/428
A61K-031/4045
A61K-009/14
A61L-031/04
출원번호
US-0525193
(2012-06-15)
등록번호
US-8852623
(2014-10-07)
발명자
/ 주소
Patel, Rajesh A.
Bucalo, Louis R.
Costantini, Lauren
Kleppner, Sofie
출원인 / 주소
Titan Pharmaceuticals, Inc.
대리인 / 주소
Morrison & Foerster LLP
인용정보
피인용 횟수 :
3인용 특허 :
98
초록▼
The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist cont
The present invention provides compositions, methods, and kits for treatment of Parkinson's disease and other conditions for which treatment with a dopamine agonist is therapeutically beneficial. The invention provides a biocompatible nonerodible polymeric device which releases dopamine agonist continuously with generally linear release kinetics for extended periods of time. Dopamine agonist is released through pores that open to the surface of the polymeric matrix in which it is encapsulated. The device may be administered subcutaneously to an individual in need of continuous treatment with dopamine agonist.
대표청구항▼
1. An implantable device for subcutaneous administration of a dopamine agonist to a mammal in need thereof, comprising a dopamine agonist and a biocompatible, nonerodible polymeric matrix, wherein said dopamine agonist is encapsulated within said matrix,wherein the polymeric matrix comprises ethylen
1. An implantable device for subcutaneous administration of a dopamine agonist to a mammal in need thereof, comprising a dopamine agonist and a biocompatible, nonerodible polymeric matrix, wherein said dopamine agonist is encapsulated within said matrix,wherein the polymeric matrix comprises ethylene vinyl acetate copolymer (EVA),wherein the implantable device is produced by an extrusion process, wherein said dopamine agonist and the polymer are blended, melted, and extruded into a structure,wherein the implantable device further comprises a coating of EVA having a lower dopamine agonist loading than the remainder of the implantable device;wherein the implantable device is washed,wherein the dopamine agonist is selected from the group consisting of lisuride, pergolide, bromocriptine, pramipexole, ropinirole, and rotigotine, andwherein when said implantable device is implanted subcutaneously in said mammal, said dopamine agonist is continuously released in vivo over a sustained period of time through pores that open to the surface of said matrix at a rate that results in a steady state plasma level of at least about 0.01 ng/ml for the sustained period of time,wherein the sustained period of time is at least about 3 months. 2. An implantable device according to claim 1, wherein said EVA comprises about 33% vinyl acetate. 3. An implantable device according to claim 1, comprising about 10 to about 85% dopamine agonist. 4. An implantable device according to claim 1, wherein said dopamine agonist is selected from the group consisting of lisuride, pergolide, and bromocriptine. 5. An implantable device according to claim 1, wherein said dopamine agonist is ropinirole. 6. An implantable device according to claim 1, wherein said dopamine agonist is pramipexole. 7. An implantable device according to claim 1, wherein said dopamine agonist is rotigotine. 8. An implantable device according to claim 1, comprising dimensions of about 2 to about 3 mm in diameter and about 2 to about 3 cm in length. 9. An implantable device according to claim 8, wherein said implantable device releases about 0.1 to about 10 mg of dopamine agonist per day in vitro. 10. An implantable device according to claim 1, further comprising an anti-inflammatory agent encapsulated within said matrix. 11. An implantable device according to claim 10, wherein said anti-inflammatory agent is a steroid. 12. An implantable device according to claim 10, wherein said anti-inflammatory agent is a nonsteroidal anti-inflammatory drug (“NSAID”). 13. An implantable device according to claim 10, wherein said anti-inflammatory agent is an antihistamine. 14. An implantable device according to claim 1, further comprising an antioxidant encapsulated within said matrix. 15. An implantable device for subcutaneous administration of a dopamine agonist to a mammal in need thereof, comprising a dopamine agonist and a biocompatible, nonerodible polymeric matrix, wherein said dopamine agonist is encapsulated within said matrix,wherein the polymeric matrix comprises ethylene vinyl acetate copolymer (EVA),wherein the implantable device is produced by an extrusion process, wherein said dopamine agonist and the polymer are blended, melted, and extruded into a structure, wherein the implantable device further comprises a coating of EVA having a lower dopamine agonist loading than the remainder of the implantable device;wherein the implantable device is washed,wherein the dopamine agonist is selected from the group consisting of lisuride, pergolide, bromocriptine, pramipexole, ropinirole, and rotigotine, andwherein when said implantable device is subcutaneously implanted in a mammal, said dopamine agonist is continuously released in vivo over a sustained period of time through pores that open to the surface of said matrix at a rate of at least about 0.1 mg of dopamine agonist per day at steady state,wherein the sustained period of time is at least about 3 months. 16. An implantable device according to claim 15, wherein said EVA comprises 33% vinyl acetate. 17. An implantable device according to claim 15, comprising about 10 to about 85% dopamine agonist. 18. An implantable device according to claim 15, wherein said dopamine agonist is selected from the group consisting of lisuride, pergolide, and bromocriptine. 19. An implantable device according to claim 15, wherein said dopamine agonist is ropinirole. 20. An implantable device according to claim 15, wherein said dopamine agonist is pramipexole. 21. An implantable device according to claim 15, wherein said dopamine agonist is rotigotine. 22. An implantable device according to claim 15, further comprising an anti-inflammatory agent encapsulated within said matrix. 23. An implantable device according to claim 22, wherein said anti-inflammatory agent is a steroid. 24. An implantable device according to claim 22, wherein said anti-inflammatory agent is a nonsteroidal anti-inflammatory drug (NSAID). 25. An implantable device according to claim 22, wherein said anti-inflammatory agent is an antihistamine. 26. An implantable device according to claim 15, further comprising an antioxidant encapsulated within said matrix. 27. A method for subcutaneous administration of a dopamine agonist to a mammal in need thereof, the method comprising administering at least one implantable device according to claim 1. 28. A method according to claim 27, wherein said at least one implantable device comprises a multiplicity of individual implantable devices, and wherein the combination of said implantable devices continuously releases dopamine agonist in vivo over a sustained period of time at a rate that results in a steady state plasma level of at least about 0.05 ng/ml for the sustained period of time. 29. A method according to claim 27, wherein said EVA comprises about 33% vinyl acetate. 30. A method according to claim 27, wherein said at least one implantable device comprises about 10 to about 85% dopamine agonist. 31. A method according to claim 27, wherein said dopamine agonist is ropinirole. 32. A method according to claim 27, wherein said dopamine agonist is pramipexole. 33. A method according to claim 27, wherein said mammal has Parkinson's disease. 34. A method according to claim 27, wherein said mammal has toxin- or disease-induced parkinsonism. 35. A method according to claim 27, wherein said mammal has a condition selected from the group consisting of erectile dysfunction and restless leg syndrome. 36. A method according to claim 27, wherein said dopamine agonist is rotigotine. 37. A method according to claim 27, wherein said dopamine agonist is selected from the group consisting of lisuride, pergolide, and bromocriptine. 38. A method according to claim 27, wherein said at least one implantable device comprises dimensions of about 2 to about 3 mm in diameter and about 2 to about 3 cm in length. 39. A method according to claim 38, wherein said at least one implantable device releases at least about 0.1 mg of dopamine agonist per day in vitro. 40. A method according to claim 27, wherein said at least one implantable device is subcutaneously implanted at a site selected from the group consisting of the upper arm, the back, and the abdomen. 41. A method according to claim 27, further comprising administration of an anti-inflammatory agent. 42. A method according to claim 41, wherein said anti-inflammatory agent is encapsulated within said matrix in said at least one implantable device. 43. A method according to claim 41, wherein said anti-inflammatory agent is encapsulated within a biocompatible, nonerodible polymeric matrix that does not comprise said dopamine agonist, and wherein said method comprises administration of said polymeric matrix comprising said anti-inflammatory agent subcutaneously. 44. A method according to claim 41, wherein said anti-inflammatory agent is administered via a route selected from the group consisting of local injection, systemic injection, subcutaneous injection, and oral administration. 45. A method according to claim 41, wherein said at least one implantable device further comprises an antioxidant. 46. A kit comprising at least one implantable device according to claim 1 and instructions for use in a method of subcutaneous administration of a dopamine agonist to a mammal in need thereof. 47. A kit according to claim 46, wherein said at least one implantable device comprises a multiplicity of individual implantable devices, and wherein when the combination of said implantable devices is implanted subcutaneously in a mammal, said implantable devices continuously release dopamine agonist in vivo over a sustained period of time at a rate that results in a steady state plasma level of at least about 0.05 ng/ml for the sustained period of time. 48. A kit according to claim 46, wherein said at least one implantable device releases dopamine agonist at a rate of at least about 0.1 mg per day in vitro. 49. A kit according to claim 46, wherein said EVA comprises about 33% vinyl acetate. 50. A kit according to claim 46, wherein said at least one implantable device comprises about 10 to about 85% dopamine agonist. 51. A kit according to claim 50, wherein said dopamine agonist is selected from the group consisting of lisuride, pergolide, and bromocriptine. 52. A kit according to claim 50, wherein said dopamine agonist is ropinirole. 53. A kit according to claim 50, wherein said dopamine agonist is pramipexole. 54. A kit according to claim 50, wherein said dopamine agonist is rotigotine. 55. An implantable device according to claim 1, wherein the steady state plasma level is about 0.01 ng/ml to about 10 ng/ml. 56. An implantable device according to claim 1, consisting essentially of the dopamine agonist, the biocompatible, nonerodible polymeric matrix, optionally an anti-inflammatory agent, and optionally an antioxidant. 57. An implantable device according to claim 15, wherein the release of the dopamine agonist results in a steady state plasma level of at least about 0.01 ng/ml for the sustained period of time. 58. An implantable device according to claim 57, wherein the steady state plasma level is about 0.01 ng/ml to about 10 ng/ml. 59. An implantable device according to claim 15, comprising dimensions of about 2 to about 3 mm is diameter and about 2 to about 3 cm in length. 60. The method according to claim 27, wherein said dopamine agonist is lisuride. 61. The method according to claim 27, wherein the steady state plasma level is about 0.01 ng/ml to about 10 ng/ml. 62. The method according to claim 27, wherein said dopamine agonist is ropinirole or rotigotine. 63. The method according to claim 27, wherein said at least one implantable device consists essentially of said dopamine agonist, said biocompatible, nonerodible polymeric matrix, optionally an anti-inflammatory agent, and optionally an antioxidant. 64. The method according to claim 27, wherein said at least one implantable device comprises about 10 to about 85% dopamine agonist, and wherein said EVA comprises about 10 to about 35% by weight vinyl acetate. 65. The method of claim 64, wherein said dopamine agonist is ropinirole. 66. The method of claim 64, wherein said dopamine agonist is lisuride. 67. The method of claim 64, wherein said dopamine agonist is pramipexole. 68. The method of claim 64, wherein said dopamine agonist is rotigotine. 69. The method according to claim 41, wherein said anti-inflammatory agent is a steroid. 70. The method according to claim 41, wherein said anti-inflammatory agent is a nonsteroidal anti-inflammatory drug (“NSAID”). 71. The method according to claim 41, wherein said anti-inflammatory agent is an antihistamine. 72. A kit according to claim 46, further comprising an anti-inflammatory agent, wherein said anti-inflammatory agent is encapsulated in at least one of said at least one implantable devices. 73. A kit according to claim 46, further comprising an anti-inflammatory agent, wherein said anti-inflammatory agent is encapsulated within a biocompatible, nonerodible polymeric matrix that does not comprise said dopamine agonist. 74. A kit according to claim 46, wherein said at least one implantable device comprises dimensions of about 2 to about 3 mm in diameter and about 2 to about 3 cm in length. 75. A kit according to claim 46, wherein the steady state plasma level is about 0.01 ng/ml to about 10 ng/ml.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (98)
Neumeyer, John L., (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers.
Yamada Minoru (Kawanishi JPX) Heya Toshiro (Takarazuka JPX) Ogawa Yasuaki (Otokuni-gun JPX), Biodegradable high-molecular polymers, production and use thereof.
Daoust, Martine; Bonhomme, Yves; Durbin, Philippe, Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator.
Sabel Bernhard A. (Munich MA DEX) Freese Andrew (Jamaica Plain MA) Saltzman William M. (Somerville MA), Controlled drug delivery system for treatment of neural disorders.
Brem Henry (Lutherville MD) Langer Robert S. (Newton MA) Domb Abraham J. (Efrat ILX), Controlled local delivery of chemotherapeutic agents for treating solid tumors.
Oshlack Benjamin (New York NY) Pedi ; Jr. Frank (Yorktown Heights NY) Chasin Mark (Manalapan NJ), Controlled release formulations coated with aqueous dispersions of acrylic polymers.
Kitchell Judith P. (Newton MA) Muni Indu A. (N. Reading MA) Boyer Yvonne N. (Salem MA), Controlled, sustained release delivery system for treating drug dependency.
Edgren David E. (El Granada CA) Bhatti Gurdish K. (Fremont CA) Carpenter Howard A. (Palo Alto CA), Dosage form for Parkinson\s disease, spasticity and muscle spasms.
El-Rashidy Ragab ; Heaton Jeremy P. W.,CAX ; Morales Alvaro,CAX ; Adams Michael A.,CAX, Dosage forms and method for ameliorating male erectile dysfunction.
David B. Masters, Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices.
Sabel Bernhard A. (Kreuzberg 6 8011 Egmating MA DEX) Freese Andrew (115 Whitcomb Ave. Jamaica Plain MA 02130), Extended drug delivery of small, water-soluble molecules.
Huc Alain (2 rue Verdi Sainte-Foy-Les-Lyon FRX) Le Pivert Patrick (2 rue Verdi 06000 Nice FRX) Gimeno Ren (Pelussin FRX), Implantable, biocompatible reservoirs permitting conservation, cellular culturing, or controlled liberation of an active.
Thomas R. Tice ; Jay K. Staas ; Teresa M. Ferrell ; Peter Markland, Injectable opioid partial agonist or opioid antagonist microparticle compositions and their use in reducing consumption of abused substances.
DePrince Randolph B. (Terre Haute IN) Viswanathan Ravi (Terre Haute IN), Layered, compression molded device for the sustained release of a beneficial agent.
Crain Stanley M. (Leonia NJ) Shen Ke-fei (Flushing NY), Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other b.
Sackler Richard (Greenwich CT) Goldenheim Paul (Wilton CT) Kaiko Robert (Weston CT), Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasm.
Poduslo Joseph F. (5719 St. Mary\s Dr. NW. Rochester MN 55901) Curran Geoffrey L. (629 23rd St. NE. Rochester MN 55906), Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents.
Muranishi Shozo (Kyoto JPX) Ikada Yoshito (Kyoto JPX) Yoshikawa Hiroshi (Kyoto JPX) Gen Shokyu (Kyoto JPX), Polylactic acid microspheres and process for producing the same.
Sabel Bernhard A. (Egmating DEX) Freese Andrew (Jamaica Plain MA) Saltzman William M. (Baltimore MD) During Matthew J. (Westport CT), Polymeric device for controlled drug delivery to the CNS.
DeLuca Patrick P. (Lexington KY) Kanke Motoko (Fukuyama JPX) Sato Toyomi (Tokyo CA JPX) Schroeder Hans G. (Encinitas CA), Porous microspheres for drug delivery and methods for making same.
Ramstack J. Michael (Lebanon OH) Herbert Paul F. (Wayland MA) Strobel Jan (Westchester OH) Atkins Thomas J. (Cincinnati OH), Preparation of biodegradable microparticles containing a biologically active agent.
Lanquetin Michel (La Trinite FRX) Thomas Jean-Louis (Charentron-le-Pont FRX) Paris Jacques (Nice FRX) Coutinho Elsimar (Salvador Bahia BRX), Subcutaneous implants based on normegestrol derivatives.
Pitt Colin G. (RTI ; P. O. Box 12194 Research Triangle Park NC 27709) Schindler Anton E. (RTI ; P. O. Box 12194 Research Triangle Park NC 27709), Sustained subdermal delivery ofdrugs using poly(e
상세보기
Randolph, Theodore W.; Manning, Mark C.; Falk, Richard F., Sustained-release composition including amorphous polymer.
Hille Thomas (Neuwied DEX) Deurer Lothar (Koblenz DEX) Hoffmann Hans-Rainer (Neuwied DEX), Transdermal therapeutic system comprising as active component buprenorphine.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.